Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade
Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 16 July 2018
Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 16 July 2018
Francesca Tucci, Valeria Calbi, Federica Barzaghi, Maddalena Migliavacca, Francesca Ferrua, Maria Ester Bernardo, Daniele Canarutto, Giulia Consiglieri, Salvatore Recupero, Francesco Calzatini, Michela Gabaldo, Caterina Lucano, Miriam Casiraghi, Silvia Darin, Francesca Dionisio, Sarah Marktel, Enza Cestone, Renato Finazzi, Giorgina Mieli‐Vergani, Enzo Boeri, Jonathan Appleby, Dalia Abd Elaziz, Fabio Ciceri, Alessandro Aiuti, Maria Pia Cicalese – 16 July 2018
Shengli Li, Zhixiang Hu, Yingjun Zhao, Shenglin Huang, Xianghuo He – 16 July 2018 – Alternative splicing (AS) is assumed to be a pivotal determinant for the generation of diverse transcriptional variants in cancer. However, the comprehensive dysregulation of AS and the prospective biological and clinical relevance in hepatocellular carcinoma (HCC) remain obscure. Here, we identified and depicted the AS landscape in HCC by performing reference‐based assembly of sequencing reads from over 600 RNA sequencing (RNA‐seq) libraries.
Jay Luther, Manish K. Gala, Nynke Borren, Ricard Masia, Russell P. Goodman, Ida Hatoum Moeller, Erik DiGiacomo, Alyssa Ehrlich, Andrew Warren, Martin L. Yarmush, Ashwin Ananthakrishnan, Kathleen Corey, Lee M. Kaplan, Sangeeta Bhatia, Raymond T. Chung, Suraj J. Patel – 16 July 2018 – Emerging data highlight the critical role for the innate immune system in the progression of nonalcoholic fatty liver disease (NAFLD).
Samuel J. Daniels, Diana J. Leeming, Mohammed Eslam, Ahmed M. Hashem, Mette J. Nielsen, Aleksander Krag, Morten A. Karsdal, Jane I. Grove, Indra Neil Guha, Takumi Kawaguchi, Takuji Torimura, Duncan McLeod, Jun Akiba, Philip Kaye, Bastiaan de Boer, Guruprasad P. Aithal, Leon A. Adams, Jacob George – 16 July 2018 – Given the high global prevalence of nonalcoholic fatty liver disease (NAFLD), the need for relevant noninvasive biomarkers and algorithms to accurately stage disease severity is a critical unmet medical need.
Anne S. Henkel – 13 July 2018
Juan Jovel, Zhen Lin, Sandra O'keefe, Steven Willows, Weiwei Wang, Guangzhi Zhang, Jordan Patterson, Carlos Moctezuma‐Velázquez, David J. Kelvin, Gane Ka‐Shu Wong, Andrew L. Mason – 12 July 2018 – Understanding the heterogeneity of dysregulated pathways associated with the development of hepatocellular carcinoma (HCC) may provide prognostic and therapeutic avenues for disease management.
Devika Kapuria, Varun K. Takyar, Ohad Etzion, Pallavi Surana, James H. O'Keefe, Christopher Koh – 6 July 2018 – Nonalcoholic fatty liver disease (NAFLD) is becoming common in the United States and throughout the world and can progress to cirrhosis, hepatocellular carcinoma, and death. There is a strong association between coronary artery disease and NAFLD due to common risk factors, such as metabolic syndrome, obesity, and diabetes mellitus.
5 July 2018
Nicholas Russo, Robert S. Brown, Nicole T. Shen, Joseph F. Pisa, Saurabh Mukewar, Zaid H. Tafesh, Russell Rosenblatt, Robert E. Schwartz, Vikas Gupta, Aleksey Novikov, Shirley Cohen‐Mekelburg – 5 July 2018